| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T864 |
0-145 |
Sentence |
denotes |
The HIV‐protease inhibitor nelfinavir (183; Figure 39) strongly inhibited replication of SARS‐CoV‐1 in Vero cells with an EC50 value of 0.048 µM. |
| T865 |
146-230 |
Sentence |
denotes |
It was suggested to exert its effect at the post‐entry step of SARS‐CoV‐1 infection. |
| T866 |
231-419 |
Sentence |
denotes |
250 Recently, Yamamoto et al reported that nelfinavir also potently inhibited replication of SARS‐CoV‐2 among nine other Anti‐HIV drugs tested (IC50, 1.13 µM; CC50, 24.32 µM; SI = 21.52). |
| T867 |
420-531 |
Sentence |
denotes |
251 The measured serum concentrations of nelfinavir were 3–6 times higher than the reported EC50 of this drug. |
| T868 |
532-616 |
Sentence |
denotes |
This indicates that it is a promising drug candidate for the management of COVID‐19. |
| T869 |
617-835 |
Sentence |
denotes |
Other drugs tested against SARS‐CoV‐2 replication were amprenavir (EC50, 31.32 µM; CC50 > 81 µM; SI > 2.59), darunavir (EC50, 46.41 µM; CC50 > 81 µM; SI > 1.75), and indinavir (EC50, 59.14 µM; CC50 > 81 µM; SI > 1.37). |
| T870 |
836-931 |
Sentence |
denotes |
Tipranavir inhibited SARS‐CoV‐2 replication as well (EC50, 3.34 µM; CC50, 76.80 µM; SI = 5.76). |
| T871 |
932-1138 |
Sentence |
denotes |
Ritonavir (EC50, 8.63 µM; CC50, 74.11 µM, SI = 8.59), saquinavir (EC50, 8.83 µM; CC50, 44.43 µM; SI = 5.03), and atazanavir (EC50, 9.36 µM; CC50 > 81 µM; SI > 8.65) suppressed SARS‐CoV‐2 at less than 10 µM. |
| T872 |
1139-1325 |
Sentence |
denotes |
Lopinavir, which was studied in SARS and COVID‐19 patients, also potently inhibited SARS‐CoV‐2 replication with the highest selectivity index (EC50, 5.73 µM; CC50, 74.44 µM; SI = 12.99). |
